A COMPANY THAT TAKES ON THE TOUGHEST HEALTH CHALLENGES BUT DOES MUCH MORE THAN JUST TREAT DISEASES
WE ARE ABBVIE, A HIGHLY FOCUSED, RESEARCH-DRIVEN BIOPHARMACEUTICAL COMPANY.

It takes a global leader to deliver patient-centered solutions around the world. We uniquely combine the assets and capabilities of an experienced pharmaceutical company with the flexibility and focus of a biotech to pursue the most meaningful opportunities for patients. The result is a biopharmaceutical company that offers new approaches to addressing today’s health issues — from life-threatening illness to chronic conditions.

We target specific difficult-to-cure diseases where we can leverage our core research and development (R&D) expertise to advance science and create solutions that go beyond treating the illness to have a positive impact on patients’ lives, as well as on economies, societies, and science itself. We look at problems holistically, from many perspectives, because that’s how you find the best solutions to the world’s increasingly complex challenges.

Contains 2015 data.

Images going clockwise:
In Tacloban in the Philippines our partner Direct Relief has clinics that support maternal health.
AbbVie and the AbbVie Foundation provide medicines and grants to relief partners to help those affected by natural disasters and to strengthen health systems, including in Bhaktapur, Nepal, after the 2015 earthquake.
Volunteers shelved some of the 21,000 books donated by the AbbVie Foundation to four schools in the United States.
Partnering with MAP International helps address Buruli ulcer in Côte d’Ivoire.
IMPACT ON PATIENTS

ABBVIE HELPS PATIENTS THROUGHOUT THEIR JOURNEY

30+ MILLION
PATIENTS TREATED BY ABBVIE’S MEDICINES EVERY YEAR GLOBALLY

PROACTIVELY MANAGING TREATMENT THROUGH ABBVIE PROGRAMS

1.37 MILLION+
PATIENTS ENROLLED IN ABBVIE PATIENT SUPPORT PROGRAMS GLOBALLY

ALMOST
1 MILLION
PATIENTS ENROLLED IN ABBVIE PATIENT SUPPORT PROGRAMS IN THE U.S.

ABBVIE IS COMMITTED TO HELPING PATIENTS

170+
COUNTRIES WHERE OUR PRODUCTS HELP PATIENTS

30+
CONDITIONS TREATED ACROSS INFANT, ADOLESCENT, ADULT, AND SENIOR STAGES OF LIFE

UNDERSTANDING THE PATIENT EXPERIENCE
ABBVIE IS COMMITTED TO UNDERSTANDING THE PATIENT EXPERIENCE ACROSS COUNTRIES AND CONDITIONS TO REDUCE BARRIERS TO TREATMENT AND AVOIDABLE HEALTHCARE SPENDING

PATIENT SUPPORT PROGRAMS

87
PROGRAMS IN THE U.S.

260+
PROGRAMS GLOBALLY
ACCESS TO MEDICINE

AbbVie supports patient assistance programs to help qualified people access their needed AbbVie medicine at no cost.

MORE THAN
81,000
U.S. PATIENTS RECEIVED MEDICINE AT NO COST

IMPROVING HEALTH OUTCOMES

We commit to target unmet needs and enhance access to healthcare across geographies. Respiratory diseases among premature babies is a leading cause of infant mortality in countries such as the Philippines, Vietnam, Turkey, and Colombia, where we work with partners to find solutions.

Across Europe, our Sustainable Healthcare initiative convenes academia, healthcare providers, patient groups, and industry stakeholders to find solutions to improve patient care while reducing costs. Learn more at abbvie.com/sustainable-healthcare.

PUTTING THE PATIENT AT THE CORE—PARTNERING TO DRIVE CHANGE ACROSS POLICIES AND PRACTICES

AbbVie collaborates with physicians and governments around the world to better address patient care. Our Good to Grow initiative is a non-promotional, multi-stakeholder program in 23 countries that aims to improve standards of care and support for premature infants. The initiative helps to develop and implement targeted public policies and care practices on neonatal health.

WORLDWIDE, 15 MILLION BABIES ARE BORN PRETERM

GOOD TO GROW EFFORTS:

- INVOLVED 17 DIFFERENT TYPES OF STAKEHOLDERS
- AND MORE THAN 20 CAMPAIGNING COALITIONS
- AND SECURED MORE THAN 10 POLICY CHANGES ON NEONATAL HEALTH
INVESTING $3.6 BILLION TO ADVANCE SCIENCE

It takes unwavering commitment and confidence to bring solutions from the petri dish to patients. AbbVie invested $3.6 billion in research and development (R&D) in 2015 to discover and test compounds with the potential to treat more than 480 million people in the world. AbbVie is deeply committed to efforts that advance science and solve the world’s toughest health challenges.

*Adjusted research and development spend per 2015 Annual Report.

6,500+ SCIENTISTS AT WORK TODAY

AbbVie’s innovation is driven by leading scientists and facilities. IDEA Pharma’s Productive Innovation Index ranked AbbVie number 5 among the top 30 pharmaceutical companies most successful at developing and commercializing new medicines.

DRIVING INNOVATION, TOGETHER

AbbVie partners with approximately 270 leading biotechs, universities, nonprofits, and government organizations to collaborate and advance science every year. The acquisition of Pharmacyclics will help to build our leadership position in oncology and strengthen our robust pipeline. Together we have the potential to transform the cancer treatment landscape.

We have an ongoing partnership with Calico, an R&D company founded by Google, to accelerate the discovery, development, and commercialization of new therapies for aging and age-related diseases, including neurodegeneration and cancer. Also, in 2016 we will launch the AbbVie Foundational Neuroscience Center in Massachusetts to spearhead our research on Alzheimer’s disease.

ADVANCING SCIENTIFIC KNOWLEDGE EVERY DAY

AbbVie received approval for 103 first-in-family patents that involved more than 500 AbbVie inventors last year. Our scientists in the medical research community published approximately 870 papers in 2015—allowing others to build on scientific knowledge we developed.

We’re also constantly looking for great ideas outside our own walls. More information is available at openinnovation.abbvie.com.

Consistent with our long-term strategy and large investment in R&D, we have a number of programs in mid- and late-stage development and continue to make significant pipeline advancements.
ABBVIE HAS A ROBUST PIPELINE

GLOBALLY THERE IS POTENTIAL TO TREAT APPROXIMATELY

482 MILLION PATIENTS LIVING WITH CONDITIONS

ABBVIE’S PIPELINE AIMS TO TREAT

82+ MILLION POTENTIAL PATIENTS LIVE IN THE UNITED STATES

OF PHASE 3/3B PIPELINE PROGRAMS ARE CONSIDERED A “NOVEL MECHANISM OF ACTION,” WHICH IS CONSIDERED “FIRST-IN-KIND” IN THE SCIENTIFIC COMMUNITY

MULTIPLE NEW MOLECULES ARE BEING STUDIED IN MORE THAN 19 CANCERS AND TUMOR TYPES

190+ ONCOLOGY CLINICAL TRIALS

32 POTENTIAL NEW MEDICINES OR NEW INDICATIONS FOR EXISTING MEDICINES IN ONCOLOGY CLINICAL TRIALS

122,000+ PATIENTS GLOBALLY

33,000+ PATIENTS IN THE U.S. PARTICIPATING IN CLINICAL TRIALS

ABBVIE ADVANCES SCIENCE THROUGH...

INVESTMENT

~ $3.6 BILLION
ADJUSTED R&D SPEND

83% OF R&D DOLLARS ARE INVESTED IN THE U.S.

NEW MOLECULAR ENTITIES (NMEs)

3 NME INDICATIONS ADVANCED TO PHASE 3

1 NME INDICATION ADVANCED TO PHASE 2 WITH REGISTRATION POTENTIAL

14 KEY PROGRAM REGISTRATION SUBMISSIONS

8 KEY PROGRAM REGULATORY APPROVALS

ABBVIE ADVANCES SCIENCE THROUGH...

OUR TALENTED EMPLOYEES

6,500+ WORKING IN SCIENCE GLOBALLY

3,900+ WORKING IN SCIENCE IN THE U.S.

1/10 ABBVIE EMPLOYEES HAVE A DOCTORAL DEGREE

1/25 WORKERS IN THE U.S.3

103 FIRST-IN-FAMILY ISSUED PATENTS

ABBVIE | 7
INVESTING IN TOUGH HEALTH CHALLENGES

An estimated 1.4 billion people—or 20 percent of the world’s population—suffer from neglected tropical diseases (NTDs).\(^4\) In response, more than 160 of AbbVie’s most experienced scientists voluntarily contributed more than 17,100 hours of expertise in 2015 to help solve NTDs. AbbVie has significant partnerships to help advance the discovery and development of new drugs for malaria, tuberculosis, onchocerciasis, lymphatic filariasis, and Chagas disease. AbbVie provided 17,000 compounds for screening and other characterization against many NTDs, performed more than 1,100 safety assays for partners’ compounds, and conducted a variety of in vivo safety and toxicology studies on lead compounds and candidates from our partners’ programs.

ABBVIE VOLUNTEERS TIME

20% OF THE WORLD’S POPULATION SUFFERS FROM NEGLECTED TROPICAL DISEASES (NTDs)\(^4\)

160+ ABBVIE SCIENTISTS VOLUNTEERED TIME TO FIND SOLUTIONS

17,100+ HOURS OF EXPERTISE TO HELP SOLVE NTDs

574 GRANTS PROVIDED IN 35 DISEASE STATES THAT ABBVIE WORKS IN

3,500+ EMPLOYEE VOLUNTEERS IN 45 COUNTRIES WHO PARTICIPATED IN WEEK OF POSSIBILITIES, ABBVIE’S SIGNATURE VOLUNTEER PROGRAM

42,000 EMPLOYEE VOLUNTEER HOURS

ABBVIE PROTECTS THE ENVIRONMENT

ABBVIE IS COMMITTED TO ENVIRONMENTAL STEWARDSHIP

FROM 2014 TO 2015, ABBVIE REDUCED GLOBAL WATER CONSUMPTION BY ROUGHLY 58 MILLION GALLONS THESE WATER SAVINGS EQUATE TO +1.1 MILLION BATHS\(^6\)

2013 TO 2015 REDUCTIONS NORMALIZED TO SALES

\(\text{CO}_2\) 19% ↓

\(\text{H}_2\text{O}\) 19% ↓

WASTE 17% ↓
THE ABBVIE FOUNDATION

The AbbVie Foundation is a non-profit 501(c)(3) entity. It is dedicated to having a remarkable impact on the lives of the underserved around the world through a commitment to building strong communities, sustainable healthcare systems, and effective educational programs. Learn more at abbviefoundation.org.

ABBVIE AND THE ABBVIE FOUNDATION DONATE MEDICINES, MONEY, AND RESOURCES

21,000+
BOOKS DONATED TO STUDENTS AND SCHOOLS IN THE U.S. BY THE ABBVIE FOUNDATION

30+ MILLION
HIV RAPID TESTS DISTRIBUTED IN 10 COUNTRIES WITH ABBVIE FOUNDATION SUPPORT

342
MEDICAL MISSIONS BY PARTNERS AMERICARES, HEART TO HEART INTERNATIONAL, MAP INTERNATIONAL, AND PROJECT HOPE

$6.3 MILLION
PRODUCT DONATIONS AND GRANTS MADE BY ABBVIE AND THE ABBVIE FOUNDATION IN RESPONSE TO NATURAL AND HUMANITARIAN DISASTERS

AbbVie and the AbbVie Foundation provide medicines and grants to relief partners to help those affected by natural disasters and to strengthen health systems, including in Bhaktapur, Nepal, after the 2015 earthquake.
EACH JOB AT ABBVIE CREATES OPPORTUNITY FOR OTHERS

We act as an economic multiplier. With more than 28,000 employees globally, our total impact on employment is up to four times that amount through direct and indirect business activity. The jobs we create pay well and attract a workforce with diverse skills and educations, including Ph.D. research scientists, laboratory technicians, support staff and more, who live, work, and spend money in their local communities. We also spend millions of dollars each year with suppliers purchasing goods and services—everything from glass containers and office supplies to electronics and injection-molded parts. This all provides benefits for third-party suppliers and local economies in the form of higher sales, tax revenue, and economic development.

One example is the significant commitment AbbVie has made to recruit, engage, and support U.S. troops and veterans as they re-enter civilian life. Our support includes: an employee resource group geared to active military and veteran employees, participation in local military base transition assistance programs, sponsorship of military hiring events, and community service focused on improving the lives of veterans.

55,000+ SUPPLIERS BENEFIT FROM OUR $10.1 BILLION IN SPENDING

In 2015, AbbVie spent more than $10.1 billion with more than 55,000 third-party suppliers across multiple industries. AbbVie creates opportunities and growth in industries that support the discovery, development, and distribution of new medicines. This investment includes diverse suppliers: AbbVie spent $854 million with more than 2,000 U.S. small and diverse-owned businesses in 2015.

ABBVIE HAS A LARGE PRESENCE AROUND THE WORLD

TOTAL MANUFACTURING AND R&D LOCATIONS

- 7 R&D RESEARCH CENTERS
- 13 MANUFACTURING FACILITIES

ABBVIE HAS A PRESENCE IN ALL 50 STATES

- ILLINOIS HOUSES OUR LARGEST EMPLOYEE BASE GLOBALLY
- 8,950 EMPLOYEES IN MASSACHUSETTS
- 840+ EMPLOYEES IN ILLINOIS
- 1,005 EMPLOYEES IN CALIFORNIA

ABBVIE CREATES JOBS & STIMULATES ECONOMIC ACTIVITY

28,000+ EMPLOYEES GLOBALLY

13,000+ EMPLOYEES IN THE U.S. AS OF JANUARY 2016

55,000+ SUPPLIERS GLOBALLY

$10.1 BILLION+

SPENT WITH THIRD PARTIES GLOBALLY

$6.1 BILLION+

SPENT WITH THIRD PARTIES IN THE U.S.
References

abbvie.com
abbvie.com/responsibility
abbviefoundation.org